Balyasny Asset Management »

Zentalis Pharmaceuticals shares owned by Balyasny Asset Management

Quarter-by-quarter ownership of Zentalis Pharmaceuticals (ZNTL) shares owned by Balyasny Asset Management from 13F filings

Historical chart of Balyasny Asset Management investment in Zentalis Pharmaceuticals

Tip: Access up to 7 years of quarterly data

All positions including Zentalis Pharmaceuticals held by Balyasny Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Zentalis Pharmaceuticals by Balyasny Asset Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $172k 11k 15.15
2023-03-31 $605k 35k 17.20
2022-09-30 $1.1M 50k 21.66

More positions owned by Balyasny Asset Management

Ishares Tr Russell 2000 Etf (IWM)
Microsoft Corporation Call Option (MSFT)
Apple (AAPL)
Invesco Qqq Tr Unit Ser 1 Call Option (QQQ)
Select Sector Spdr Tr Financial (XLF)
Spdr S&p 500 Etf Tr Tr Unit (SPY)
Hess Put Option (HES)
Invesco Exchange Traded Fd T S&p500 Eql Wgt (RSP)
Amazon (AMZN)
JPMorgan Chase & Co. Call Option (JPM)
Ishares Tr Core S&p Mcp Etf (IJH)
Union Pacific Corporation Call Option (UNP)
Select Sector Spdr Tr Technology (XLK)
Boeing Company (BA)
Deere & Company (DE)

View all positions for Balyasny Asset Management

Top funds holding Zentalis Pharmaceuticals

Eventide Asset Management
Vanguard Group
Citadel Advisors
T. Rowe Price Associates
Federated Investors
Decheng Capital
PRIMECAP Management Company
Dimensional Fund Advisors
Bank of America Corporation
Logos Global Management
5AM Venture Management
Caption Management
Boxer Capital
Charles Schwab Investment Management
Paradigm Biocapital Advisors

View all funds holding Zentalis Pharmaceuticals